Neoleukin Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Neurogene

05/05/2023 13:56

* Neoleukin Therapeutics Inc  NLTX.OQ   NLTX.O  is expected
to show no change in quarterly revenue when it reports 
results on May 8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Neoleukin
Therapeutics
Inc is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 11.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $2​, above​ its last closing price of $0.89.
​​​

This summary was machine generated May 5 at 12:56 GMT.  All
figures in US dollars  unless otherwise stated